Bio-Path (NASDAQ:BPTH) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH) in a report released on Thursday morning. The firm issued a sell rating on the stock.

Separately, Roth Mkm restated a “buy” rating and issued a $20.00 price objective on shares of Bio-Path in a report on Monday, July 8th.

Bio-Path Price Performance

NASDAQ BPTH opened at $0.91 on Thursday. The company has a 50 day simple moving average of $1.01 and a 200-day simple moving average of $1.76. Bio-Path has a 52-week low of $0.85 and a 52-week high of $13.90.

Bio-Path (NASDAQ:BPTH) last issued its earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period in the previous year, the company posted ($10.60) earnings per share. Research analysts predict that Bio-Path will post -6.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned approximately 4.66% of Bio-Path as of its most recent filing with the SEC. Hedge funds and other institutional investors own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.